Made Scientific Acquires 85,000 Sq. Ft. Pennsylvania Facility to Expand Cell Therapy Manufacturing
Event summary
- Made Scientific acquired an 85,000 sq. ft. operational cell therapy manufacturing facility in East Norriton, Pennsylvania, on September 18, 2026.
- The facility is immediately operational with 145 GMP batches executed across multiple autologous and allogeneic programs, including CAR-T and B-cell therapies.
- The acquisition brings Made Scientific's U.S. East Coast footprint to approximately 145,000 sq. ft. with 15 qualified GMP manufacturing suites.
- The facility includes eight Grade B/C cleanrooms, one Grade C ballroom, one Grade B fill-finish suite, and 30,000 sq. ft. of expansion space.
- Made Scientific is preparing its Princeton facility for FDA pre-licensure inspection in early 2027, with the East Norriton facility to follow.
The big picture
The acquisition positions Made Scientific to capitalize on the growing demand for cell therapy manufacturing capacity as more therapies advance into late-phase trials and regulatory review. The operational facility provides immediate scalability, reducing transition risk for sponsors and aligning with the company's long-term strategy of building a robust manufacturing network. This move comes as the broader CDMO sector consolidates, highlighting Made Scientific's ability to add qualified capacity at a critical juncture.
What we're watching
- Capacity Utilization
- How quickly Made Scientific can onboard new client programs and utilize the expanded manufacturing capacity in East Norriton.
- Regulatory Milestones
- The timeline and outcome of the FDA pre-licensure inspections for both the Princeton and East Norriton facilities in 2027.
- Market Consolidation
- Whether Made Scientific can sustain its growth amidst broader cell therapy CDMO sector consolidation and increasing demand for manufacturing partners.
Related topics